The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Real-world data on prophylactic corticosteroid use with axi-cel in patients with R/R LBCL
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares insights into the findings of a study that assessed real-world practice patterns on the use of prophylactic dexamethasone with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Lin explains that the real-world adoption of prophylactic dexamethasone varied significantly across different centers in the US. Dr Lin also comments on an early-stage real-world study aiming to compare the outcomes of patients that have received prophylactic corticosteroids to those that have not. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bluebird Bio: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Legend: Consultancy; Juno: Consultancy; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Gamida Cell: Consultancy; Takeda: Research Funding; Vineti: Consultancy; Sorrento: Consultancy; Merck: Research Funding.
